author={Harriet M. Bryson and Rex N. Brogden},
AbstractSynopsisCombining tazobactam, a β-lactamase inhibitor, with the ureidopenicillin, piperacillin, successfully restores the activity of piperacillin against β-lactamase-producing bacteria. Tazobactam has inhibitory activity, and therefore protects piperacillin against Richmond and Sykes types II, III, IV and V β-lactamases, staphylococcal penicillinase and extended-spectrum β-lactamases. However, tazobactam has only species-specific activity against class I chromosomally-mediated enzymes… 

The Quinazolinone Allosteric Inhibitor of PBP 2a Synergizes with Piperacillin and Tazobactam against Methicillin-Resistant Staphylococcus aureus

The proposed mechanism for the synergistic activity in MRSA involves inhibition of the β-lactamase by tazobactam, which protects piperacillin from hydrolysis, which can then inhibit its target, PBP 2, which becomes vulnerable to inhibition in the presence of the quinazolinone.

Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Ceftolozane in an In Vitro Infection Model

D dose fractionation studies designed to determine the exposure measure most predictive of tazobactam efficacy in combination with ceftolozane and the magnitude of this measure necessary for efficacy in a PK-PD in vitro infection model are described.

Cost Efficacy of Tazobactam/Piperacillin versus Imipenem/Cilastatin in the Treatment of Intra-Abdominal Infection

Compared with imipenem/cilastatin, tazobactam/piperacillin is more cost efficacious in the treatment of intra-abdominal infections and that it offers a cost advantage through fewer relapses and lower daily therapeutic costs.

Single-Dose Pharmacokinetics of Piperacillin/Tazobactam in Hispaniolan Amazon Parrots (Amazona ventralis)

Results indicate that p Piperacillin is rapidly absorbed and reaches high initial concentrations; however, it is also rapidly eliminated in the Hispaniolan Amazon parrot, and tazobactam has similar pharmacokinetics as piperacillin.

Eleutheroside K isolated from Acanthopanax henryi (Oliv.) Harms suppresses methicillin resistance of Staphylococcus aureus

Investigating the antibacterial activity of the single constituent of Eleutheroside K, isolated from the leaves of A. henryi (Oliv.) Harms, against methicillin‐resistant Staphylococcus (S.) aureus confirmed that it significantly suppressed MRSA infections and emphasized the potential application of ETSK as a novel anti‐MRSA natural drug.

Influence of substrates and inhibitors on the structure of Klebsiella pneumoniae carbapenemase-2

This work focuses on cataloging the available KPC-2 structures and presenting a discussion of key aspects of each structure and important relationships between structures, and features new analyses and interpretations of the existing structures which will impact the field in a positive way by making structural insights more widely available among the beta-lactamase community.

Novel insights into the chemistry of an old medicine: A general degradative pathway for penicillins from a piperacillin/tazobactam stability study.

  • A. ViolaL. Ferrazzano W. Cabri
  • Biology
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  • 2019

Strategies to Overcome Antimicrobial Resistance (AMR) Making Use of Non-Essential Target Inhibitors: A Review

The author focuses on the discovery of antibiotic adjuvants and on new tools to study and reduce the prevalence of resistant bacterial infections.




Imipenem/cilastatin is effective as initial monotherapy of a variety of infections, including infections in neutropenic patients, with a clear role in empirical treatment of mixed infection.

Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of escherichia coli and proteus mirabilis harbouring known β-lactamases

Strains ofEscherichia coli and Proteus mirabilis harboring known β-lactamases showed significant differences in susceptibilities to the various combinations, suggesting that, at least in strains resistant to one combination, several β-Laktamase-Inhibitor-Kombination combinations should be tested in the laboratory.

Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate

For relatively susceptible strains of members of the family Enterobacteriaceae, neither combination was predictably more active than the other, but relatively resistant strains were generally more susceptible to piperacillin-tazobactam.

Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam.

Tazobactam and clavulanic acid were superior to sulbactam in enhancing the therapeutic efficacy of piperacillin in mice infected with beta-lactamase-positive E. coli, K. pneumoniae, Proteus mirabilis, and Staphylococcus aureus.

Effect of piperacillin/tazobactam therapy on intestinal microflora.

The effect of piperacillin/tazobactam treatment upon the intestinal microflora was studied in 20 patients with intraabdominal infections and there was a minor decrease in the number of bifidobacteria, eubacteria, lactobacilli, clostridia and veillonella but the numbers of anaerobic Gram-positive cocci and bacteroides were not influenced by the treatment.

Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830).

  • R. JonesA. Barry
  • Biology, Medicine
    Diagnostic microbiology and infectious disease
  • 1989

Susceptibility of beta-lactamase-producing enterococci to piperacillin with tazobactam.

Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases.

The piperacillin + tazobactam combination, unlike ticarcillin + clavulanate, showed some degree of synergy against most derepressed strains of these species, but it is in the last two species that these enzymes pose the greatest resistance threat.

Susceptibility of anaerobes in phase 3 clinical studies of piperacillin/tazobactam.

In this study, the in vitro susceptibility of anaerobic pathogens to piperacillin/tazobactam and other antimicrobial agents used in the treatment ofAnaerobic infections was determined based on results for 532 isolates obtained from patients enrolled in clinical trials for evaluation of the safety and efficacy of the p Piperacillin-tazOBactam combination.

Evaluation of piperacillin-tazobactam in experimental meningitis caused by a beta-lactamase-producing strain of K1-positive Escherichia coli

Combination treatment of piperacillin combined with tazobactam in experimental meningitis resulted in significantly better bactericidal activity in the cerebrospinal fluid.